Protocol No.: EZH-302

SYMPHONY-1: A Phase 1B/3 Double-blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat/EPZ-6438 or Placebo in Combination with Lenalidomide plus Rituximab (R^2) in Subjects with Relapsed/Refractory Follicular Lymphoma
Principal Investigator
Bhatnagar, Bhavana
Phase
III
Age Group
Adult
Applicable Disease Site
Lymphoma
Participating Institution
Wheeling Hospital
Contact
Maher Kali, MD
Clinical Research Specialist-WVUCI
Phone: +1 304-243-7045

View on ClinicalTrials.gov